Patents by Inventor Michael Miley

Michael Miley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for dengue virus vaccines and diagnostics
    Patent number: 10772948
    Abstract: The present invention provides compositions directed to recombinant flavivirus E glycoprotein ectodomain dimers for use in diagnostic and immunotherapeutic methods.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: September 15, 2020
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Stefan Metz, Aravinda Desilva, Michael Miley
  • METHODS AND COMPOSITIONS FOR DENGUE VIRUS VACCINES AND DIAGNOSTICS
    Publication number: 20180280494
    Abstract: The present invention provides compositions directed to recombinant flavivirus E glycoprotein ectodomain dimers for use in diagnostic and immunotherapeutic methods.
    Type: Application
    Filed: September 20, 2016
    Publication date: October 4, 2018
    Inventors: Stefan Metz, Aravinda Desilva, Michael Miley
  • Disulfide trap MHC class I molecules and uses therefor
    Patent number: 8992937
    Abstract: A disulfide trap, comprising an antigen peptide covalently attached to an MHC class I heavy chain molecule by a disulfide bond extending between two cysteines, is disclosed. In some configurations, a disulfide trap, such as a disulfide trap single chain trimer (dtSCT), can comprise a single contiguous polypeptide chain. Upon synthesis in a cell, a disulfide trap oxidizes properly in the ER, and can be recognized by T cells. In some configurations, a peptide moiety of a disulfide trap is not displaced by high-affinity competitor peptides, even if the peptide binds the heavy chain relatively weakly. In various configurations, a disulfide trap can be used for vaccination, to elicit CD8 T cells, and in multivalent MHC/peptide reagents for the enumeration and tracking of T cells. Also disclosed are nucleic acids comprising a sequence encoding a disulfide trap. Such nucleic acids, which can be DNA vectors, can be used as vaccines.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: March 31, 2015
    Assignee: Washington University
    Inventors: Ted H. Hansen, Daved Fremont, Janet Connolly, Lonnie Lybarger, Michael Miley, Vesselin Mitaksov, Steven Truscott
  • Disulfide Trap MHC Class I Molecules and Uses Therefor
    Publication number: 20090117153
    Abstract: A disulfide trap, comprising an antigen peptide covalently attached to an MHC class I heavy chain molecule by a disulfide bond extending between two cysteines, is disclosed. In some configurations, a disulfide trap, such as a disulfide trap single chain trimer (dtSCT), can comprise a single contiguous polypeptide chain. Upon synthesis in a cell, a disulfide trap oxidizes properly in the ER, and can be recognized by T cells. In some configurations, a peptide moiety of a disulfide trap is not displaced by high-affinity competitor peptides, even if the peptide binds the heavy chain relatively weakly. In various configurations, a disulfide trap can be used for vaccination, to elicit CD8 T cells, and in multivalent MHC/peptide reagents for the enumeration and tracking of T cells. Also disclosed are nucleic acids comprising a sequence encoding a disulfide trap. Such nucleic acids, which can be DNA vectors, can be used as vaccines.
    Type: Application
    Filed: August 28, 2007
    Publication date: May 7, 2009
    Inventors: Ted H. Hansen, David H. Fremont, Janet Connolly, Lonnie Lybarger, Michael Miley, Vesselin Mitaksov, Steven Truscott